COGT vs. IMNM, AYTU, ARWR, XENE, PTCT, FOLD, MOR, IDYA, MRVI, and DYN
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Immunome (IMNM), Aytu BioPharma (AYTU), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), PTC Therapeutics (PTCT), Amicus Therapeutics (FOLD), MorphoSys (MOR), IDEAYA Biosciences (IDYA), Maravai LifeSciences (MRVI), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Cogent Biosciences (NASDAQ:COGT) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, community ranking, media sentiment, institutional ownership and profitability.
In the previous week, Cogent Biosciences had 1 more articles in the media than Immunome. MarketBeat recorded 5 mentions for Cogent Biosciences and 4 mentions for Immunome. Immunome's average media sentiment score of 0.98 beat Cogent Biosciences' score of 0.24 indicating that Immunome is being referred to more favorably in the news media.
Cogent Biosciences currently has a consensus target price of $14.67, suggesting a potential upside of 83.10%. Immunome has a consensus target price of $29.80, suggesting a potential upside of 99.46%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than Cogent Biosciences.
Cogent Biosciences received 249 more outperform votes than Immunome when rated by MarketBeat users. Likewise, 70.62% of users gave Cogent Biosciences an outperform vote while only 69.44% of users gave Immunome an outperform vote.
Immunome has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Cogent Biosciences has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500.
44.6% of Immunome shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by company insiders. Comparatively, 8.6% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Cogent Biosciences has a net margin of 0.00% compared to Immunome's net margin of -1,829.44%. Immunome's return on equity of -37.33% beat Cogent Biosciences' return on equity.
Summary
Immunome beats Cogent Biosciences on 12 of the 17 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
